{"id":"NCT02736721","sponsor":"Hoffmann-La Roche","briefTitle":"Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)","officialTitle":"Multicenter Open Label Expanded Access-Program of Pegylated Interferon Alfa-2a (Pegasys) in Patients With Chronic Myelogenous Leukemia (CML)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-09","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2016-04-13","resultsPosted":"2016-08-05","lastUpdate":"2016-09-20"},"enrollment":41,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myelogenous Leukemia, Chronic"],"interventions":[{"type":"DRUG","name":"Peginterferon alfa-2a","otherNames":["Pegasys"]}],"arms":[{"label":"Peginterferon alfa-2a","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy, safety and tolerability of long-term use of peginterferon alfa-2a in participants with CML who have previously participated in peginterferon alfa-2a study ML16544 (NCT number not available), NO16006 (NCT number not available) or ML17228 (NCT number not available) and treating physician has decided to continue treatment with peginterferon alfa-2a within the frame of another clinical study.","primaryOutcome":{"measure":"Number of Participants With Complete Hematologic Response","timeFrame":"Up to approximately 7 years","effectByArm":[{"arm":"Peginterferon Alfa-2a","deltaMin":40,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":5,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":41},"commonTop":["Arthralgia","Depression","Fatigue","Influenza like illness","Bronchitis"]}}